{"id":"W2570141807","doi":"10.1016/j.jaad.2016.11.041","title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":860,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Internal medicine; Placebo; Adverse effect; Surgery; Gastroenterology; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003367701,0.001305646,0.002412334,0.0003677801,0.0003656981,0.001124018,0.0008075305,0.001565831,0.004182272],"category_scores_gemma":[0.002232046,0.0005459982,0.002118596,0.0002943936,0.001010621,0.0007821096,0.0003393526,0.002797666,0.0006681898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006273599,"about_ca_system_score_gemma":0.000657035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005541359,"about_ca_topic_score_gemma":0.001038114,"domain_scores_codex":[0.9986845,0.0008395176,0.00008691145,0.0001657802,0.0001127803,0.0001105919],"domain_scores_gemma":[0.9985393,0.0004641838,0.0004701269,0.00008309138,0.00007700909,0.0003663002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9802125,0.002490021,0.0008254774,0.0004602576,0.001250874,0.00001605558,0.00003226465,0.0001428732,0.002162674,0.00003316213,0.0003658211,0.01200811],"study_design_scores_gemma":[0.9133201,0.07866468,0.005178634,0.00006155662,0.001159248,0.0000430969,0.00001989473,0.0003098863,0.0006488473,0.00008427331,0.0004961381,0.00001375],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819178,0.01407914,0.0004118276,0.0005594323,0.0003577842,0.0007880526,0.0007040794,0.00005023114,0.001131693],"genre_scores_gemma":[0.9914384,0.004240502,0.000551693,0.0005943265,0.0004557981,0.0007598206,0.0007717882,0.00001718404,0.001170382],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004182272,"threshold_uncertainty_score":0.01781034,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03413351889159199,"score_gpt":0.3233729633831536,"score_spread":0.2892394444915616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}